/PRNewswire/ Actimed Therapeutics Ltd announces that following regulatory approval from the UK Regulatory Agency, it has commenced a clinical study in.
- Divestments of UK oral liquid products streamlines the portfolio and furthers Essential Pharma's international growth strategy - Acquired products are low volume, but essential medicines
LoQus23 Therapeutics exits stealth with £11 5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ LoQus23 Therapeutics Ltd. ( LoQus23 ), a company discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat.
/PRNewswire/ LoQus23 Therapeutics Ltd. ( LoQus23 ), a company discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat.